Items where authors include "Seymour, MT"

Article

Hall, PS, Cairns, DA orcid.org/0000-0002-2338-0179 and Seymour, MT orcid.org/0000-0002-2441-9629 (2021) Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population—Reply. JAMA Oncology, 7 (11). 1725. ISSN 2374-2437

Hoorn, ST, Sommeijer, DW, Elliot, F et al. (12 more authors) (2021) Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer. ISSN 0007-0920

Yin, J, Cohen, R, Jin, Z et al. (23 more authors) (2021) Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute. ISSN 0027-8874

Hall, PS, Swinson, D, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (32 more authors) (2021) Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA oncology, 7 (6). pp. 869-877. ISSN 2374-2437

Craig, SG, Humphries, MP, Alderdice, M et al. (21 more authors) (2020) Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 123. pp. 1280-1288. ISSN 0007-0920

Rao, S, Sclafani, F, Eng, C et al. (18 more authors) (2020) International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology, 38 (22). pp. 2510-2518. ISSN 0732-183X

Baaten, ICPA, West, NP orcid.org/0000-0002-0346-6709, Quyn, AJ et al. (2 more authors) (2020) Colorectal cancer peritoneal metastases: Biology, treatment and next steps. EJSO - European Journal of Surgical Oncology, 46 (4). pp. 675-683. ISSN 0748-7983

Burzykowski, T, Coart, E, Saad, ED et al. (24 more authors) (2019) Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2 (9). e1911750.

Salem, ME, Yin, J, Weinberg, BA et al. (18 more authors) (2018) Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer, 103. pp. 205-213. ISSN 0959-8049

Seligmann, JF, Hatch, AJ, Richman, SD orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2018) Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncology, 4 (4). pp. 564-568. ISSN 2374-2437

Sjoquist, KM, Renfro, LA, Simes, RJ et al. (31 more authors) (2017) Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 10 (6). djx253. ISSN 0027-8874

Bosch, LJW, Trooskens, G, Snaebjornsson, P et al. (21 more authors) (2017) Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 8 (38). pp. 63140-63154. ISSN 1949-2553

Seligmann, JF and Seymour, MT orcid.org/0000-0002-2441-9629 (2017) Editorial: Use of Gene Expression Profiles to Distinguish Molecular Subtypes in Colorectal Cancer: Progression Toward Primetime. JNCI: Journal of the National Cancer Institute, 109 (7). djx019. ISSN 0027-8874

Renfro, LA, Goldberg, RM, Grothey A et al. (24 more authors) (2017) Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology, 35 (17). pp. 1929-1937. ISSN 0732-183X

Hall, PS, Lord, SR, Collinson, M et al. (12 more authors) (2017) A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British Journal of Cancer, 116. pp. 472-478. ISSN 0007-0920

Salem, ME, Yin, J, Renfro, LA et al. (15 more authors) (2017) Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. Journal of Clinical Oncology, 35 (Supplement 4). p. 675. ISSN 0732-183X

Franko, J, Shi, Q, Meyers, JP et al. (17 more authors) (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17 (12). pp. 1709-1719. ISSN 1470-2045

Schoon, J, Brock, IW, Cox, A et al. (7 more authors) (2016) The effect of single nucleotide polymorphisms on clinical outcome and survival in the FOCUS (fluorouracil, oxaliplatin and irinotecan: use and sequencing) clinical trial of metastatic colorectal cancer. Anticancer Research, 36 (12). ABSTR055. pp. 6717-6718. ISSN 0250-7005

Seligmann, JF, Elliott, F, Richman, SD et al. (7 more authors) (2016) Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA oncology, 2 (5). pp. 633-642. ISSN 2374-2437

Handforth, C, Clegg, A orcid.org/0000-0001-5972-1097, Young, C orcid.org/0000-0001-5709-4413 et al. (4 more authors) (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Annals of Oncology, 26 (6). pp. 1091-1101. ISSN 0923-7534

Venderbosch, S, Nagtegaal, ID, Maughan, TS et al. (13 more authors) (2014) Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 20 (20). pp. 5322-5330. ISSN 1078-0432

Lieu, CH, Renfro, LA, De Gramont, A et al. (8 more authors) (2014) Association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD clinical trials program. Journal of Clinical Oncology, 32 (27). pp. 2975-2982. ISSN 0732-183X

Maughan, TS, Meade, AM, Adams, RA et al. (22 more authors) (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110 (9). 2178 - 2186. ISSN 0007-0920

Sommeijer, DW, Shi, Q, Meyer, J et al. (17 more authors) (2013) Prognostic value of Early Objective Tumor Resonse (EOTR) to first line systemic therapy in Metastatic Colorectal Cancer (MCRC): Individual Patient Data (IPD) meta-analysis of randomized trials from the ARCAD database. Asia-Pacific Journal of Clinical Oncology, 9 (S3). 76 - 76. ISSN 1743-7555

Seymour, MT, Brown, SR, Middleton, G et al. (18 more authors) (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14 (8). 749 - 759. ISSN 1470-2045

Madi, A, Fisher, D, Wilson, RH et al. (9 more authors) (2012) Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer, 107 (7). pp. 1037-1043. ISSN 0007-0920

Seymour, MT (2011) Sequential Chemotherapy for Colorectal Cancer. Lancet Oncology, 12. 1 - 2 (2). ISSN 0140-6736

Brown, SR, Gregory, WM, Twelves, CJ et al. (5 more authors) (2011) Designing phase II trials in cancer: a systematic review and guidance. British Journal of Cancer, 105 (2). 194 - 199 . ISSN 1532-1827

Hennig, IM, Naik, JD, Brown, S et al. (8 more authors) (2008) Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin. Journal of Clinical Oncology, 26 (20). 3411 - 3417. ISSN 0732-183X

Conference or Workshop Item

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Hall, P, Swinson, D, Lord, S et al. (7 more authors) (2019) Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial. In: 44th ESMO Congress (ESMO 2019), 27 Sep - 01 Oct 2019, Barcelona, Spain.

Proceedings Paper

Williams, C, Emmerson, J, Beggs, AD et al. (12 more authors) (2022) A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442). In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting, 03-07 Jun 2022, Online & Chicago, IL, USA. American Society of Clinical Oncology .

Swinson, D, Hingorani, M, Stokes, Z et al. (15 more authors) (2019) Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, USA. American Society of Clinical Oncology , p. 4051.

Seymour, MT orcid.org/0000-0002-2441-9629 and Morton, D (2019) FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. In: Journal of Clinical Oncology. ASCO 2019, 31 May - 04 Jun 2019, Chicago. American Society of Clinical Oncology (ASCO) , p. 3504.

Hall, PS, Swinson, D, Waters, JS et al. (17 more authors) (2019) Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, USA. American Society of Clinical Oncology .

Turnbull, SJ, West, E, Scott, K et al. (3 more authors) (2018) Chemotherapy to reverse diminished immune responses (IRs) associated with a raised neutrophil lymphocyte ratio (NLR) in patients with advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology, 24 May 2018. American Society of Clinical Oncology .

Ferraro, DA, Zalcberg, JR, Shi, Q et al. (3 more authors) (2018) Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database. In: Journal of Clinical Oncology. 2018 Gastrointestinal Cancers Symposium, 18-20 Jan 2018, San Francisco, CA, USA. American Society of Clinical Oncology .

Richman, SD orcid.org/0000-0003-3993-5041, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Seligmann, JF, Fisher, D, Smith, CG et al. (8 more authors) (2016) Exploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 03-07 Jun 2016, Chicago, Il. American Society of Clinical Oncology .

Laurent-Puig, P, Paget-Bailly, S, Vernerey, D et al. (12 more authors) (2015) Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial. In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Seligmann, JF, Fisher, D, Elliott, F et al. (8 more authors) (2015) Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Seligmann, JF, Elliott, F, Jacobs, B et al. (10 more authors) (2015) HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Handforth, C, Hall, PS, Marshall, HC et al. (3 more authors) (2013) Overall treatment utility: a novel outcome measure reflecting the balance of benefits and harms from cancer therapy. In: European Journal of Cancer. European Cancer Congress, 2013, Amsterdam, The Netherlands. Elsevier , S346 - S346.

Handforth, C, Hall, PS, Marshall, HC et al. (3 more authors) (2013) The feasibility of using comprehensive geriatric assessment in frail or elderly patients with advanced gastric or oesophageal cancer. In: European Journal of Cancer. European Cancer Congress 2013, 2013, Amsterdam, The Netherlands. Elsevier , S348 - S348.